---
title: "Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278261754.md"
description: "Bank of America Securities has reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) following its earnings report. Analyst Alec Stranahan set a price target of $15, which is the lowest among Wall Street estimates. Despite being listed as one of the 13 Most Profitable Growth Stocks to Buy Right Now, the bearish outlook reflects concerns about the company's performance."
datetime: "2026-03-08T10:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278261754.md)
  - [en](https://longbridge.com/en/news/278261754.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278261754.md)
---

# Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) with a price target of $15, based on the report released on February 27. The firm’s price target is the lowest among Wall \[…\]

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance](https://longbridge.com/en/news/282227475.md)
- [This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday](https://longbridge.com/en/news/282051007.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)